Read now

CNS-ICNA 2020

Discover the conference highlights

Apolipoprotein E ε4 and attentional abilities in Down syndrome

Takeaway

  • Apolipoprotein E ε4 (APOE ε4) is associated with an attentional advantage during early development but infers a disadvantage later in life in individuals with Down syndrome (DS).

Why this matters

  • Alzheimer’s disease (AD) risk is uncommonly high in individuals with DS, and in carriers of the APOE ε4 allele regardless of DS diagnosis; and while studies have shown APOE ε4 to infer a cognitive advantage in typical development, this has not been explored in children with DS.

  • Revealing a similar APOE ε4 effect pattern in DS individuals as in their typically developing counterparts is useful to inform further research into the increased AD risk in this cohort, and for targeting AD treatment at different developmental stages for optimal quality of life.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.